We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » JANSSEN DRAWS WARNING LETTER FOR RISPERDAL PROMOTION
JANSSEN DRAWS WARNING LETTER FOR RISPERDAL PROMOTION
April 28, 2004
The FDA’s Division of Drug, Marketing, Advertising and Communication (DDMAC) has issued a warning letter to Janssen Pharmaceutica regarding a “Dear Healthcare Provider” (DHP) letter that included misleading claims about the company’s atypical antipsychotic drug Risperdal.